Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Omada Health vs PeptidesRx

Omada Health
Graded #435

Lower grade

vs+8.800000000000004
PeptidesRx
Graded #240

Higher grade

The verdict

PeptidesRx takes it — 64.4/100 to 55.6/100.

PeptidesRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. PeptidesRx is a Fort Worth, TX-based licensed telehealth platform offering physician-supervised compounded semaglutide, tirzepatide, and a broader prescription peptide menu.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valuePeptidesRx +17
45
62
Dose & formulationPeptidesRx +14
40
54
Clinical oversightPeptidesRx +8
77
85
Labs & monitoringOmada Health +6
61
55
FulfillmentPeptidesRx +8
62
70
Contract termsEven
55
55
Omada Health · left barPeptidesRx · right bar

The numbers

MetricOmada HealthPeptidesRx
WeighScore55.6/10064.4/100
GradeCC
Scorecard rank#435#240
SemaglutideNot disclosed$169/mo (0.25 mg dose, compounded)
TirzepatideNot disclosed$309/mo (2.5 mg dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Omada Health

Graded #435 · C

Strengths

  • Added GLP-1 prescribing and medication management in late 2025
  • Clinicians trained in obesity care, available in all 50 states
  • Behavioral support wrapped before, during and after treatment
  • GLP-1 Flex Care adds a cash-pay medication pathway in 2026
  • Publicly traded, evidence-based virtual care platform

Where it loses points

  • Core program distributed via employers and health plans, limited cash-pay
  • GLP-1 prescribing is a recent addition still scaling
  • GLP-1 Flex Care only rolling out to employers later in 2026
  • No transparent published price for the core member program
PeptidesRx

Graded #240 · C

Strengths

  • Compliance-focused positioning vs gray-market vendors
  • Board-certified medical director
  • Transparent pricing with no surprise fees
  • Real prescriptions, not research-chemical channel

Where it loses points

  • Smaller scale than Henry Meds or Hims
  • Wide peptide menu may distract from GLP-1 focus

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard